21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
22:18 , Jun 23, 2017 |  BioCentury  |  Finance

Synthetic vitality

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit. Repare emerged from stealth mode...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Repare launches with $68M series A

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds...
11:45 , Jun 22, 2017 |  BC Extra  |  Financial News

Repare launches with $68M

Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ, the Celgene...
11:03 , Jun 22, 2017 |  BC Innovations  |  Emerging Company Profile

Repare in progress

With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via...
07:00 , Sep 26, 2016 |  BioCentury  |  Finance

Damage control

SV Life Sciences is going back for seconds in DNA damage repair, leading a $33.2 million series A round for Artios Pharma Ltd. This time, the firm is building the company for the long term...
07:00 , Sep 21, 2016 |  BC Extra  |  Financial News

Artios launches with $33.2M

Cancer newco Artios Pharma Ltd. (Cambridge, U.K.) raised $33.2 million in a series A round led by SV Life Sciences . Merck Ventures, Imperial Innovations Group plc (LSE:IVO), Arix Bioscience plc, the CRT Pioneer Fund...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA-directed DNA polymerase θ (POLQ); poly(ADP-ribose) polymerase (PARP)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting POLQ could help treat cancers deficient in homologous recombination (HR) or homology-directed DNA repair. In a human breast cancer cell line with compromised homology-directed repair,...